174508-13-5CC(CN(C)C)CN1c2ccccc2S(=O)(=O)c2ccccc21QTQPVLDZQVPLGV-UHFFFAOYSA-NOxomemazine is a member of phenothiazines.
174508-13-5、174508-14-6、3689-50-7DTXSID5023405CHEMBL2104734安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。
Danger
H301 (83.3%): Toxic if swallowed [Danger Acute toxicity, oral]
P260, P261, P262, P264, P270, P271, P272, P273, P280, P284, P301+P316, P301+P317, P302+P352, P304+P340, P316, P320, P321, P330, P333+P317, P361+P364, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 6 reports by companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
R - Respiratory system
QR - Respiratory system
来歴The development of oxomemazine is the result of a systematic exploration of phenothiazine compounds in the mid-20th century. Following the significant sedative effects of the first-generation antihistamine promethazine, scientists focused on optimizing its pharmacological properties through structural modification. In the late 1950s and early 1960s, researchers synthesized oxomemazine by chemically modifying the side chains of promethazine. This new compound retained potent antihistamine activity while enhancing its antitussive and sedative effects. Based on these properties, oxomemazine was marketed as an antitussive in the 1960s, often under the brand name Toplexil®, and was particularly suitable for treating allergic dry cough accompanied by sleep disturbances.
使用(±)-Oxomemazine, is a phenothiazine-type antihistamines, that has also shown antibacterial activity against Mycobacterium tuberculosis.
現在のフィルター条件では反応記録がありません。
読み込み中…
CHEBI:135408